Key clinical point: Zoledronic acid did not affect progression of AAC in postmenopausal women with osteoporosis.
Major finding: Over 3 years, AAC progressed in 29% of women given zoledronic acid once a year and 31% of those given a placebo (P = 0.64).
Study details: The data come from a post hoc analysis of 502 postmenopausal women in the HORIZON study.
Disclosures: The study was supported by Novartis Pharmaceuticals. Lead author Dr. Cai had no financial conflicts to disclose.
Cai G et al. Osteoporosis Int. 2020 May 2. doi: 10.1007/s00198-020-05430-z.